On a day of competing earnings calls by the two leaders in the immuno-oncology space, Bristol-Myers Squibb Co. did not back down from the challenge being posed by Merck & Co. Inc. and its PD-1 inhibitor Keytruda (pembrolizumab), as well as that company’s efforts to establish PD-L1 expression as an efficacy biomarker.
Bristol execs told the firm’s April 28 first quarter earnings call that Opdivo (nivolumab) is on pace for success, despite...